The Patient Tearing Up My Waiting Room Is Why Cebranopadol Matters
Tris Pharma presents cebranopadol (TRN-228) dual NOP/MOP data at CPDD 2026. For patients with comorbid chronic pain and OUD,...
PSYCH PULSE
ADHD Dosing Has Two Failure Modes, and Trials Are Designed to Miss Both
A Lancet Psychiatry network meta-analysis of ADHD pharmacotherapy exposes therapeutic inertia and uncritical dose escalation as twin hazards—with direct…
The IT Neuron Finding That Should Reshape How We Design Rapid-Acting Depression Trials
New Cell data pinpoints intratelencephalic neurons in the anterior insula as the mechanistic key to aiTBS antidepressant effects—here's what...
France Just Approved What the U.S. Still Won’t Name: IV Ketamine for Acute Suicidal Crisis
France's March 2026 approval of intravenous racemic ketamine for severe suicidal crisis is the first regulatory action of its...